Adam Kaplin, M.D., Ph.D.
Chief Scientific Officer
Adam Kaplin, M.D., Ph.D. was appointed Chief Scientific Officer of MyMD effective December 18, 2020. Prior to joining MyMD, Dr. Kaplin has served in several positions at John Hopkins University, including Principal Neuro-Psychiatric Consultant to the Johns Hopkins Multiple Sclerosis Center of Excellence, Director of the Johns Hopkins Ketamine Clinic, and the Departments of Psychiatry & Neurology at Johns Hopkins University School of Medicine, positions he has held at various times from 2002 to present. In addition, since 2019, Dr. Kaplin has served as Adjunct Faculty at the George Mason University Department of Global and Community Health. Dr. Kaplin has also served as Co-Founder of numerous healthcare related startups, including, from 2018 to present, REWARD Pathways Inc., a company devoted to addiction treatment development focused on a combined eHealth and medicine approach to curing addiction, and from 2016 to present, Hollinger Kaplin Benjamin & Bond, an eHealth software development company. Dr. Kaplin’s research focuses on the investigation of the biological basis of immune mediated depression and cognitive impairment by using MS as the model. Dr. Kaplin has also been active for over a decade in the development and application of health information technology to mental health, combining this work with providing neuropsychiatric consultation and ongoing care of patients with MS spectrum disorders. Dr. Kaplin’s original research has been published over 40 times in several different publications, and he has authored or co-authored numerous review articles and textbooks. Dr. Kaplin received his B.S. in Biology from Yale University, graduating cum laude in 1988, and received his M.D. and Ph.D. from the Johns Hopkins University School of Medicine in 1996.
- Professional Activities
- Research and Publications
- News Articles and Media Coverage
- Review Editor, Frontiers in Neurology, Frontiers in Neuroscience and Frontiers in Psychiatry, 2019
- Scientific and Medical Advisor on CBT for MS Project, Pear Therapeutics, 2017
- Founding Medical Advisor; Member of Board of Advisors, Cure Addiction Now, 2017
- Medical Advisor, Memotext, 2016
- Medical Advisor, MS Cure Project, 2015
- Steering Committee Member, Johns Hopkins University Global mHealth Initiative (JHU-GmI), 2014
- Board of Scientific Advisors, Apellis Pharmaceutical, 2014
- Board of Advisors, Crisis Text Line, 2013
- Board of Scientific Advisors, Anthrotronix, 2012
- Board of Medical Advisors, Remedy Health, 2008
- Scientific and Medical Advisor, Nancy Davis Center Without Walls MS Foundation, 2005
- Board Member and Chief Scientific Advisor, Cody Unser First Step Foundation, 2005
- Faculty Member, Member of the Scientific Advisory Council and Operating Committee, Johns Hopkins Project RESTORE, 2004
- Chairman of Scientific Advisory Board, Montel Williams MS Foundation, 2003
- Medical Advisory Board Member, International Transverse Myelitis Association, 2002
The following three publications for MyMD Pharmaceuticals, Inc. were published/accepted in Q3 or 2022 (1&2) and Q1 of 2023 (3).
- Journal of Drug Research
A Double-blind, Placebo-controlled, Randomized, Single Ascending, and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Dose of MYMD1™ Capsules in Healthy Male and Female Adult SubjectsCitation: Brager J, Chapman C, Dunn L, Kaplin A. A Double-blind, Placebo-controlled, Randomized, Single Ascending, and Multiple Dose Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Dose Isomyosamine Capsules in Healthy Adult Subjects. Drug Res (Stuttg). 2022 Nov 11. doi: 10.1055/a-1962-6834. Epub ahead of print. PMID: 36368677.
- British Society of Immunology, Liverpool, UK December 5-8, 2022
Pharmacology and clinical profile of MYMD-1® (isomyosamine), an oral, selective, next-generation, TNF-alpha inhibitor that crosses the blood brain barrier
Jenna Brager, Ronald Christopher, Adam Kaplin, Chris Chapman - 62nd Annual Meeting and ToxExpo, Society of Toxicology March 19-23, 2023 in Nashville, TN
A Naturally Occurring Novel Therapeutic and Oral Selective Inhibitor of TNFa, MYMD-1 (Isomyosamine), Significantly Reduced the Inflammation and Disease Severity in Murine Model of Collagen Antibody-Induced Arthritis
Chris Chapman, and Sonia Edaye - Wang M, Kaplin AI. “Explaining naltrexone’s interference with ketamine’s antidepressant effect.” Am J Psychiatry. 2019 May;176:5/li>
- Hollinger KR, Alt J, Rais R, Kaplin AI, Slusher BS. “The NAAG’ing concerns of modeling human Alzheimer’s disease in mice.” J Alzheimers Dis. 2019;68(3):939-945
- Kalmbach DA, Fang Y, Arnedt JT, Cochran AL, Deldin PJ, Kaplin AI, Sen S. “Effects of sleep, physical activity, and shift work on daily mood: A prospective mobile monitoring study of medical interns.” J Gen Intern Med. 2018 Jun;33(6):914-920
- Hollinger KR, Woods SR, Adams-Clark A, Choi SY, Franke CL, Susukida R, Thompson C, Reti IM, Kaplin AI. “Defense automated neurobehavioral assessment accurately measures cognition in patients undergoing electroconvulsive therapy for major depressive disorder.” J ECT. 2018 Mar;34(1):14-20
- Pinto MD, Greenblatt AM, Williams BL, Kaplin AI. “Exploring the mechanism of the clinical encounter on depressive symptoms in young adults: A path analysis.” Issues Ment Health Nurs. 2017 Jul;38(7):533-539
Paxil Unsafe for Teenagers, KCSW,
People with Paralysis Explore Therapeutic Effects of Scuba Diving, Washington Post, Sept. 15, 2014
Apps for Mastering Your Mood, Time, July 18, 2013
Sharing Psychiatric Records Helps Care, New York Times, Jan. 7, 2013
How Keeping Psych Records Too Private Can Hurt Patient Care, Time, Jan. 7, 2013
Clues in the Cycle of Suicide, New York Times, June 24, 2013
Apps Alert the Doctor When Trouble Looms, New York Times, Oct. 8, 2012
Scuba Diving Could Raise Hope for the Paralyzed, CBS News, Oct. 27, 2011
Scuba Diving May Hold Promise for Paraplegic, Baltimore Sun, Oct. 15, 2011